Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,034 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hematopoietic Stem Cell Transplantation (HSCT) Clear all
Completed Phase 2 Interventional

Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

NCT00201799
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Infliximab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
20 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional

Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

NCT04117477
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Xylitol, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 15, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

NCT05501756
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Alemtuzumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients

NCT02617407
View directory record Official record
Conditions
Dental Plaque
Interventions
Livionex® Dental Gel, PreviDent 5000 plus/Tom's of Maine Children's toothpaste, Kolibree Toothbrush
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Not applicable Interventional

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

NCT02326675
View directory record Official record
Conditions
Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions
Ice, Normal Saline Solution
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

NCT00661544
View directory record Official record
Conditions
Multiple Myeloma, Stem Cell Transplantation
Interventions
Arsenic Trioxide, Melphalan, Ascorbic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 15, 2026, 9:06 AM EDT
Not yet recruiting No phase listed Observational

PRAISE-IR Versus CIBMTR Controls

NCT07717164
View directory record Official record
Conditions
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Interventions
Not listed
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
1 Year to 66 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

NCT00943319
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma
Interventions
Busulfan, Fludarabine, Campath, Stem Cell Transplant
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

NCT03298412
View directory record Official record
Conditions
High-risk Diffuse Large B-cell Lymphoma
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

NCT00005851
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Aurora, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional

Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

NCT01950507
View directory record Official record
Conditions
Stem Cell Transplantation, Graft vs Host Disease
Interventions
Budesonide, Fluconazole, Voriconazole, Micafungin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00005092
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
Cyclophosphamide, Psoralen, Thiotepa, Allogeneic bone marrow transplantation, In vitro-treated peripheral blood stem cell transplantation (PBSCT), Radiation Therapy (RT)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

NCT02312102
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Lenalidomide, Velcade
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Problem-Solving Skills Training for Parents of Children Undergoing Hematopoietic Stem Cell Transplantation: A Feasibility Study

NCT07219524
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Bright Ideas Problem-Solving Skills Training
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 15, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

NCT00005986
View directory record Official record
Conditions
Leukemia
Interventions
busulfan, cyclophosphamide, filgrastim, recombinant interferon alfa, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cemiplimab in AlloSCT/SOT Recipients With CSCC

NCT04339062
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Interventions
Cemiplimab, Everolimus, Sirolimus, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

NCT00453388
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Oakland, California • Nashville, Tennessee • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

NCT00588094
View directory record Official record
Conditions
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Not applicable Interventional

High Dose Vitamin D Replacement in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT02876822
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

NCT00677859
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
MultiStem®
Biological
Lead sponsor
Healios K.K.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 15, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

NCT00002461
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, sargramostim, carmustine, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Montefiore Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 1991
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 15, 2026, 9:06 AM EDT
Terminated Phase 1Phase 2 Interventional

Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

NCT00032773
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
pentostatin for injection
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 15, 2026, 9:06 AM EDT